BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Aimo A, Fabiani I, Vergaro G, Arzilli C, Chubuchny V, Pasanisi EM, Petersen C, Poggianti E, Taddei C, Pugliese NR, Bayes-Genis A, Lupón J, Giannoni A, Ripoli A, Georgiopoulos G, Passino C, Emdin M. Prognostic value of reverse remodelling criteria in heart failure with reduced or mid-range ejection fraction. ESC Heart Fail 2021;8:3014-25. [PMID: 34002938 DOI: 10.1002/ehf2.13396] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
Number Citing Articles
1 Correale M, Mazzeo P, Tricarico L, Croella F, Fortunato M, Magnesa M, Amatruda M, Alfieri S, Ferrara S, Ceci V, Dattilo G, Mele M, Iacoviello M, Brunetti ND. Pharmacological Anti-Remodelling Effects of Disease-Modifying Drugs in Heart Failure with Reduced Ejection Fraction. Clin Drug Investig 2022. [PMID: 35726047 DOI: 10.1007/s40261-022-01166-2] [Reference Citation Analysis]
2 Yamada S, Bartunek J, Behfar A, Terzic A. Mass Customized Outlook for Regenerative Heart Failure Care. Int J Mol Sci 2021;22:11394. [PMID: 34768825 DOI: 10.3390/ijms222111394] [Reference Citation Analysis]
3 Aimo A, Fabiani I, Vergaro G, Arzilli C, Chubuchny V, Pasanisi EM, Petersen C, Poggianti E, Taddei C, Pugliese NR, Bayes-Genis A, Lupón J, Giannoni A, Ripoli A, Georgiopoulos G, Passino C, Emdin M. Prognostic value of reverse remodelling criteria in heart failure with reduced or mid-range ejection fraction. ESC Heart Fail 2021;8:3014-25. [PMID: 34002938 DOI: 10.1002/ehf2.13396] [Cited by in F6Publishing: 3] [Reference Citation Analysis]